GlassScriptPhysician profile
Michael Teixido
NPI 1487695987
$2,786.40
in general payments reported to CMS, 2019-2025
26 companies · $579 in 2025
The $579 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $116 · 2021: $491 · 2022: $482 · 2023: $424 · 2024: $406 · 2025: $579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,408.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.76 | 2021-2025 | Qulipta, Ubrelvy |
| Integra Lifesciences Corporation | $229.48 | 2019-2025 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Biocryst US Sales Co., LLC | $219.11 | 2021-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $191.98 | 2019-2022 | |
| Pfizer INC. | $184.25 | 2023-2025 | |
| Csl Behring | $137.96 | 2023-2025 | Haegarda, Hizentra, Andembry |
| Biohaven Pharmaceuticals, INC. | $127.76 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $110.77 | 2022 | |
| Amgen INC. | $60.81 | 2020-2022 | |
| Incyte Corporation | $54.50 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $48.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.07 | 2023 | Hyqvia |
| Cochlear Americas | $35.19 | 2025 | Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Baha |
| Glaxosmithkline, LLC. | $33.95 | 2025 | Nucala |
| Arbor Pharmaceuticals, INC. | $33.68 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Bionics, LLC | $31.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.00 | 2019 | |
| Allergan, INC. | $24.30 | 2020 | |
| Upsher-Smith Laboratories LLC | $24.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.47 | 2019 | |
| Hill Dermaceuticals, INC. | $20.98 | 2021 | |
| Genzyme Corporation | $20.04 | 2020 | |
| Lundbeck LLC | $18.16 | 2024 | Vyepti |
| Axsome Therapeutics, INC. | $15.68 | 2025 | Symbravo |
| Optinose US, INC. | $14.87 | 2021 | |
| Biocryst Pharmaceuticals, INC. | $11.85 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Teixido listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.